Senate investigations panel to probe Mylan's EpiPen pricingWASHINGTON (Reuters) - The U.S. Senate’s permanent subcommittee on investigations will probe Mylan Pharmaceuticals’ pricing of the allergy auto-injector EpiPen, according to a press release issued on Wednesday. The release described the probe as a “preliminary inquiry.” Mylan has been criticized - including by Democratic presidential candidate Hillary Clinton - for sharply raising the price of EpiPens, which are carried by people with life-threatening allergies. Mylan raised the price from about $100 in 2008 to about $600 currently. It has offered some discounts but this has done little to allay concerns. “Our review of this matter will be robust, thorough, and bipartisan. Parents and school districts in Ohio, Missouri and across the country need affordable access to this life-saving drug, and we share their concern over Mylan’s sustained price increases,” Senators Rob Portman, the Republican chair of the subcommittee, and Claire McCaskill, the top Democrat, said in a statement. Mylan did not immediately respond to a request for comment. politicsNews
senate investigations panel probe milan pipe pricingwashington reuters the senate permanent subcommittee investigations probe milan pharmaceuticals pricing allergy pipe according press release issued wednesday the release described probe preliminary milan criticized including democratic presidential candidate hillary clinton sharply raising price pipes carried people allergies milan raised price currently it offered discounts done little ally concerns our review matter robust thorough bipartisan parents school districts ohio missouri across country need affordable access drug share concern milan sustained price increases senators rob portal republican chair subcommittee claire mccaskill top democrat said statement milan immediately respond request comment politicsnews
Your task is to classify the provided input as real or fake news. Label 0 is meant for fake news, Label 1 is for real news. TEXT: Senate investigations panel to probe Mylan's EpiPen pricingWASHINGTON (Reuters) - The U.S. Senate’s permanent subcommittee on investigations will probe Mylan Pharmaceuticals’ pricing of the allergy auto-injector EpiPen, according to a press release issued on Wednesday. The release described the probe as a “preliminary inquiry.” Mylan has been criticized - including by Democratic presidential candidate Hillary Clinton - for sharply raising the price of EpiPens, which are carried by people with life-threatening allergies. Mylan raised the price from about $100 in 2008 to about $600 currently. It has offered some discounts but this has done little to allay concerns. “Our review of this matter will be robust, thorough, and bipartisan. Parents and school districts in Ohio, Missouri and across the country need affordable access to this life-saving drug, and we share their concern over Mylan’s sustained price increases,” Senators Rob Portman, the Republican chair of the subcommittee, and Claire McCaskill, the top Democrat, said in a statement. Mylan did not immediately respond to a request for comment. politicsNews
Your task is to classify the provided input as real or fake news. Label 0 is meant for fake news, Label 1 is for real news. TEXT: senate investigations panel probe milan pipe pricingwashington reuters the senate permanent subcommittee investigations probe milan pharmaceuticals pricing allergy pipe according press release issued wednesday the release described probe preliminary milan criticized including democratic presidential candidate hillary clinton sharply raising price pipes carried people allergies milan raised price currently it offered discounts done little ally concerns our review matter robust thorough bipartisan parents school districts ohio missouri across country need affordable access drug share concern milan sustained price increases senators rob portal republican chair subcommittee claire mccaskill top democrat said statement milan immediately respond request comment politicsnews